WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 206121
Description: Ethaselen, also known as BBSKE, is a novel organoselenium thioredoxin reductase inhibitor, is currently being investigated in a phase I clinical trial in China. Ethaselen enhanced the efficacy of radiation therapy both in vivo and in vitro without observable toxicity. BBSKE was found to suppress irradiation-induced NF-κB activation dramatically when using A549 cells stably transfected with NF-κB luciferase reporter. Ethaselen is a potentially promising agent for the treatment of patients with NSCLC clinically.
MedKoo Cat#: 206121
Chemical Formula: C16H12N2O2Se2
Exact Mass: 423.92292
Molecular Weight: 422.2
Elemental Analysis: C, 45.52; H, 2.86; N, 6.64; O, 7.58; Se, 37.40
Synonym: Ethaselen; EB; BBSKE.
IUPAC/Chemical Name: 2,2'-(ethane-1,2-diyl)bis(benzo[d][1,2]selenazol-3(2H)-one) .
InChi Key: SFFSGPCYJCMDJM-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H12N2O2Se2/c19-15-11-5-1-3-7-13(11)21-17(15)9-10-18-16(20)12-6-2-4-8-14(12)22-18/h1-8H,9-10H2
SMILES Code: O=C1N(CCN2[Se]C3=CC=CC=C3C2=O)[Se]C4=CC=CC=C14
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 422.2 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Wang L, Yang Z, Fu J, Yin H, Xiong K, Tan Q, Jin H, Li J, Wang T, Tang W, Yin J, Cai G, Liu M, Kehr S, Becker K, Zeng H. Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent. Free Radic Biol Med. 2012 Mar 1;52(5):898-908. doi: 10.1016/j.freeradbiomed.2011.11.034. Epub 2011 Dec 21. PubMed PMID: 22210352.
2: Wang L, Fu JN, Wang JY, Jin CJ, Ren XY, Tan Q, Li J, Yin HW, Xiong K, Wang TY, Liu XM, Zeng HH. Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy. Anticancer Drugs. 2011 Sep;22(8):732-40. doi: 10.1097/CAD.0b013e32834618bc. PubMed PMID: 21562407.
3: Zhou HY, Meng ZY, Dou GF, Ma JL, Lou YQ, Zhang GL. [LC-MSn analysis of metabolites of 1,2-[bis (1,2-benzisoselenazolone-3(2H)-ketone)]-ethane, a novel anti-cancer agent in rat]. Yao Xue Xue Bao. 2010 May;45(5):627-31. Chinese. PubMed PMID: 20931766.
4: Yin H, Li J, Xiong K, Wang L, Wang T, Tan Q, Fu J, Ren X, Zeng H. Novel mechanism of ethaselen in poorly differentiated colorectal RKO cell growth inhibition: Simultaneous regulation of TrxR transcription, expression and enzyme activity. Differentiation. 2011 Jan;81(1):49-56. doi: 10.1016/j.diff.2010.09.180. PubMed PMID: 20864247.
5: Liu M, Fu J, Li J, Wang L, Tan Q, Ren X, Peng Z, Zeng H. Preparation of tri-block copolymer micelles loading novel organoselenium anticancer drug BBSKE and study of tissue distribution of copolymer micelles by imaging in vivo method. Int J Pharm. 2010 May 31;391(1-2):292-304. doi: 10.1016/j.ijpharm.2010.03.001. Epub 2010 Mar 6. PubMed PMID: 20211232.
6: Fu JN, Li J, Tan Q, Yin HW, Xiong K, Wang TY, Ren XY, Zeng HH. Thioredoxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest. Invest New Drugs. 2011 Aug;29(4):627-36. doi: 10.1007/s10637-010-9401-y. Epub 2010 Mar 2. PubMed PMID: 20195699.
7: Tan Q, Ren XY, Li J, Wang F, Deng SJ, Zeng HH. [Correlation of plasma thioredoxin reductase activity to growth of H22 hepatocellular carcinoma xenografts in Kunming mice]. Ai Zheng. 2009 May;28(5):472-7. Chinese. PubMed PMID: 19624873.
8: Tan Q, Li J, Yin HW, Wang LH, Tang WC, Zhao F, Liu XM, Zeng HH. Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo. Invest New Drugs. 2010 Jun;28(3):205-15. doi: 10.1007/s10637-009-9235-7. Epub 2009 Mar 7. PubMed PMID: 19271154.
9: Li X, Yang Z, Yang K, Zhou Y, Chen X, Zhang Y, Wang F, Liu Y, Ren L. Self-assembled polymeric micellar nanoparticles as nanocarriers for poorly soluble anticancer drug ethaselen. Nanoscale Res Lett. 2009 Sep 16;4(12):1502-11. doi: 10.1007/s11671-009-9427-2. PubMed PMID: 20652138; PubMed Central PMCID: PMC2893964.
10: Zhou HY, Dou GF, Meng ZY, Lou YQ, Zhang GL. Development of a rapid and sensitive liquid chromatography/tandem mass spectrometry method for the determination of 1,2-[bis(1,2-benzisoselenazolone-3(2H)-ketone)]-ethane (BBSKE), a novel anti-cancer agent in rat plasma. Biomed Chromatogr. 2008 Oct;22(10):1123-9. doi: 10.1002/bmc.1034. PubMed PMID: 18651605.